|
|
|
| Research progress in fibroblast growth factor 21 in metabolic diseases |
| CHANG Hongkai1, ZHAO Dong2. |
| 1.Luhe Hospital of Capital Medical University, Beijing 101199, China; 2.Endocrinology Center, Luhe Hospital of Capital Medical University, Beijing 101199, China |
|
| Cite this article: |
|
CHANG Hongkai,ZHAO Dong. Research progress in fibroblast growth factor 21 in metabolic diseases[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2023, 53(12): 1015-1022.
|
|
|
|
Abstract Fibroblast growth factor 21 (FGF21) is an atypical member of the fibroblast growth factor (FGF) superfamily and is secreted into blood to act mainly in target tissues, including brain, liver, adipose tissue, skeletal muscle and pancreas islet via a heterodimeric receptor complex comprising fibroblast growth factor receptor (FGFR1) and coreceptor β-Klotho. Previous studies suggest that FGF21 can decrease blood glucose levels and body weight. Targeting FGF21 has emerged as an option for nonalcoholic steatohepatitis (NASH) therapy. The current clinical trials indicate that FGF21 has the potential for the treatment of nonalcoholic steatohepatitis.However, the effect of FGF21 analog on liver histology, clinical outcome and safety needs to be further verified with a larger number of patients. This review summarizes the mechanism and recent development of FGF21 functions in metabolic diseases and related clinical drug research advances, which might provide a suitable reference for clinical management.
|
|
Received: 05 June 2023
|
| |
|
|
|
|
|
|
